Hyperuricemia as a predictive marker for progression of nephrosclerosis: Clinical assessment of prognostic factors in biopsy-proven arterial/arteriolar nephrosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 24, Issue 6, 2017, Pages 630-642

  Momoki, Kumiko ^a   Kataoka, Hiroshi ^a   Moriyama, Takahito ^a   Mochizuki, Toshio ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Arterial arteriolar sclerosis; Biopsy; Hyperuricemia; Nephrosclerosis; Prognosis

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; MALE; NEPHROSCLEROSIS; PREDICTIVE VALUE; PROGNOSTIC ASSESSMENT; PROPENSITY SCORE; PROTEINURIA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; MIDDLE AGED; NEPHRITIS; PATHOLOGY; PROGNOSIS; RENOVASCULAR HYPERTENSION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; BIOPSY; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; NEPHRITIS; NEPHROSCLEROSIS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 85020179218     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.37523     Document Type: Article

References (62)

1. Nenov VD, Taal MW, Sakharova OV, Brenner BM: Multi-hit nature of chronic renal disease. Current Opinion in Nephrology and Hypertension 2000; 9: 85-97
2. Taal MW, Brenner BM: Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney International 2006; 70: 1694-1705
3. Yu HT: Progression of chronic renal failure. Arch Intern Med 2003; 163: 1417-1429
4. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919
5. Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ: Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006; 17: 2928-2936
6. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953
7. Reynolds K, Gu D, Muntner P, Kusek JW, Chen J, Wu X, Duan X, Chen CS, Klag MJ, Whelton PK, He J: A popu- lation-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol 2007; 18: 1928-1935
8. Regalado M, Yang S, Wesson DE: Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35: 687-694
9. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schafer K, Sieberth HG, Wanner C, Watschinger B, Zuc-chelli P: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926-931
10. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR: Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998; 13: 1430-1437
11. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feld-man HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
13. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373
14. Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Ame-miya N, Watanabe Y, Honda K, Mochizuki T, Nitta K: Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clinical and Experimental Nephrology 2012; 16: 706-712
15. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Annals of Internal Medicine 2006; 144: 21-28
16. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Perez de Jose A, Cedeno S, Linares T, Luno J: Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis 2015; 65: 543-549
17. Vikse BE, Aasarod K, Bostad L, Iversen BM: Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrology Dialysis Transplantation 2003; 18: 517-523
18. Dasgupta I, Porter C, Innes A, Burden R: 'Benign' hypertensive nephrosclerosis. Qjm-an International Journal of Medicine 2007; 100: 113-119
19. Sumida K, Hoshino J, Ueno T, Mise K, Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Fujii T, Ohashi K, Takaichi K, Ubara Y: Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis. PLoS One 2016; 11: e0147690
20. Kumar V, Abbas AK, Fausto N: Robbins and Cotran pathologic basis of disease. 9th ed, ed by Kumar V, Abbas AK and Fausto N, pp938-939, Saunders, Philadelphia, PA: 2015
21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992
22. Lash TL, Mor V, Wieland D, Ferrucci L, Satariano W, Silliman RA: Methodology, design, and analytic techniques to address measurement of comorbid disease. J Gerontol A Biol Sci Med Sci 2007; 62: 281-285
23. Ording AG, Sorensen HT: Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. Clin Epidemiol 2013; 5: 199-203
24. Tracy RE, Ishii T: What is ‘nephrosclerosis’? lessons from the US, Japan, and Mexico. Nephrol Dial Transplant 2000; 15: 1357-1366
25. Meyrier A: Nephrosclerosis: update on a centenarian. Nephrol Dial Transplant 2015; 30: 1833-1841
26. Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kre-mers WK, Textor SC, Stegall MD: The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med 2010; 152: 561-567
27. Kopp JB: Rethinking hypertensive kidney disease: arterio-nephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens 2013; 22: 266-272
28. Moritz AR, Oldt MR: Arteriolar Sclerosis in Hypertensive and Non-Hypertensive Individuals. Am J Pathol 1937; 13: 679-728
29. Luke RG: Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2271-2278
30. Hsu CY: Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertens 2002; 11: 267-272
31. Tracy RE: Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 1996; 16: 126-133
32. Meyrier A, Simon P: Nephroangiosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant 1996; 11: 2116-2120
33. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Katafuchi R, Hirakata H, Okuda S, Tsuneyoshi M, Sueishi K, Fujishima M, Iida M: Risk factors for renal glomerular and vascular changes in an autopsy-based population survey: the Hisayama study. Kidney Int 2003; 63: 1508-1515
34. Erten S, Gungor O, Sen S, Ozbek SS, Kircelli F, Hos-coskun C, Toz H, Asci G, Basci A, Ok E: Nephrosclerosis and carotid atherosclerosis: lessons from kidney donor histology. Nephrology (Carlton) 2011; 16: 720-724
35. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153-1159
36. Boers M, Croonen AM, Dijkmans BA, Breedveld FC, Eulderink F, Cats A, Weening JJ: Renal findings in rheu-matoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis 1987; 46: 658-663
37. Katz SM, Korn S, Umlas SL, DeHoratius RJ: Renal vascular lesions in systemic lupus erythematosus. Ann Clin Lab Sci 1990; 20: 147-153
38. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
39. Shimizu M, Furuichi K, Yokoyama H, Toyama T, Iwata Y, Sakai N, Kaneko S, Wada T: Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol 2014; 18: 305-312
40. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH: Resurrection of uric acid as a causal risk factor in essential hypertension. In: Hypertension. United States; 2005: 18-20
41. Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS: Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33
42. Forman JP, Choi H, Curhan GC: Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18: 287-292
43. Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takishita S: Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 835-841
44. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS: Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19: 1204-1211
45. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M: Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56: 264-272
46. Zoppini G, Targher G, Chonchol M, Ortalda V, Abater-usso C, Pichiri I, Negri C, Bonora E: Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012; 35: 99-104
47. Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS: High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33: 1337-1343
48. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M: Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001; 87: 333-339
49. Syrjanen J, Mustonen J, Pasternack A: Hypertriglyceridae-mia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
50. Wu J, Chen X, Xie Y, Yamanaka N, Shi S, Wu D, Liu S, Cai G: Characteristics and risk factors of intrarenal arterial lesions in patients with IgA nephropathy. Nephrol Dial Transplant 2005; 20: 719-727
51. Moriyama T, Itabashi M, Takei T, Kataoka H, Sato M, Shimizu A, Iwabuchi Y, Nishida M, Uchida K, Nitta K: High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. J Nephrol 2015; 28: 451-456
52. Akalin E, Ganeshan SV, Winston J, Muntner P: Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation 2008; 86: 652-658
53. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650
54. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS: Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342-350
55. Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K, Sakima A, Iseki K, Ohya Y: An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 2013; 36: 43-49
56. Kojima C, Takei T, Ogawa T, Nitta K: Serum complement C3 predicts renal arteriolosclerosis in non-diabetic chronic kidney disease. J Atheroscler Thromb 2012; 19: 854-861
57. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106
58. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2-7
59. Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, Johnson RJ: Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 2012; 121: e71-78
60. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-275
61. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-75
62. Chen Y, Xu B, Sun W, Sun J, Wang T, Xu Y, Xu M, Lu J, Li X, Bi Y, Wang W, Ning G. Impact of the Serum Uric Acid Level on Subclinical Atherosclerosis in Middle-aged and Elderly Chinese. J Atheroscler Thromb 2015; 22: 823-832